![Casper Hansen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Casper Hansen
Vorstandsvorsitzender bei Pcovery ApS
Aktive Positionen von Casper Hansen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Pcovery ApS
![]() Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | 01.02.2013 | - |
Vorstandsvorsitzender | 01.02.2013 | - | |
Embark Laboratories ApS
![]() Embark Laboratories ApS BiotechnologyHealth Technology Embark Laboratories ApS is a Danish biotech company that focuses on cardiometabolic disease. The private company is based in Copenhagen, Denmark. The company was founded in 2023. Casper Tind Hansen has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | 07.05.2023 | - |
Vorstandsvorsitzender | 07.05.2023 | - |
Karriereverlauf von Casper Hansen
Ehemalige bekannte Positionen von Casper Hansen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Embark Biotech ApS
![]() Embark Biotech ApS Miscellaneous Commercial ServicesCommercial Services Novo Nordisk Research Center Gladsaxe ApS is based in Bagsværd, Denmark. The Danish company is a spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. The company discovered a novel target that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity. The development of the target was initiated through a collaboration with Novo Nordisk and further matured with support from the Innobooster program at the Innovation Fund Denmark and the Bioinnovation Institute (BII) during a residency in the Venture House program. Part of Novo Nordisk A/S, Novo Nordisk Research Center Gladsaxe ApS is a biotech company that was founded in 2017. The CEO of the company is Casper Tind Hansen. Novo Nordisk Research Center Gladsaxe was acquired by Novo Nordisk A/S from Embark Laboratories ApS on August 28, 2023 for $68.06 million. | Direktor/Vorstandsmitglied | - | 29.08.2023 |
Vorstandsvorsitzender | - | 29.08.2023 | |
Novo Ventures 1 A/S
![]() Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Corporate Officer/Principal | 01.01.2008 | 01.01.2013 |
Churney ApS
![]() Churney ApS Data Processing ServicesTechnology Services Churney ApS is a company based in Copenhagen, Denmark. The Danish company was founded by Casper Tind Hansen, Christian Hansen, Noy Rotbart, Brian Brost. Noy Rotbart has been the CEO of the company since 2021. | Gründer | 01.05.2021 | - |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - | - |
H. LUNDBECK A/S | Vertrieb & Marketing | - | - |
Adenium Biotech ApS
![]() Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Casper Hansen
University of Copenhagen | Graduate Degree |
Statistik
International
Dänemark | 10 |
Operativ
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 5 |
Finance | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
H. LUNDBECK A/S | Health Technology |
Private Unternehmen | 7 |
---|---|
Adenium Biotech ApS
![]() Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Pcovery ApS
![]() Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Novo Ventures 1 A/S
![]() Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
Embark Biotech ApS
![]() Embark Biotech ApS Miscellaneous Commercial ServicesCommercial Services Novo Nordisk Research Center Gladsaxe ApS is based in Bagsværd, Denmark. The Danish company is a spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. The company discovered a novel target that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity. The development of the target was initiated through a collaboration with Novo Nordisk and further matured with support from the Innobooster program at the Innovation Fund Denmark and the Bioinnovation Institute (BII) during a residency in the Venture House program. Part of Novo Nordisk A/S, Novo Nordisk Research Center Gladsaxe ApS is a biotech company that was founded in 2017. The CEO of the company is Casper Tind Hansen. Novo Nordisk Research Center Gladsaxe was acquired by Novo Nordisk A/S from Embark Laboratories ApS on August 28, 2023 for $68.06 million. | Commercial Services |
Embark Laboratories ApS
![]() Embark Laboratories ApS BiotechnologyHealth Technology Embark Laboratories ApS is a Danish biotech company that focuses on cardiometabolic disease. The private company is based in Copenhagen, Denmark. The company was founded in 2023. Casper Tind Hansen has been the CEO of the company since 2023. | Health Technology |
Churney ApS
![]() Churney ApS Data Processing ServicesTechnology Services Churney ApS is a company based in Copenhagen, Denmark. The Danish company was founded by Casper Tind Hansen, Christian Hansen, Noy Rotbart, Brian Brost. Noy Rotbart has been the CEO of the company since 2021. | Technology Services |
- Börse
- Insiders
- Casper Hansen
- Erfahrung